Isopropyl-phosphonsaeure-diphenylester | 1538-72-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Isopropyl-phosphonsaeure-diphenylester
• 英文别名: Phosphonic acid, (1-methylethyl)-, diphenyl ester；[phenoxy(propan-2-yl)phosphoryl]oxybenzene
• CAS: 1538-72-3
• 化学式: C₁₅H₁₇O₃P
• 分子量: 276.272
• InChiKey: HKYWEKLIWPYEOV-UHFFFAOYSA-N

物化性质

• 沸点：
  198-200 °C(Press: 10.5 Torr)
• 密度：
  1.1497 g/cm3(Temp: 100 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  亚磷酸三苯酯 在 乙醇 作用下， 生成 Isopropyl-phosphonsaeure-diphenylester
  参考文献：
  名称：

  Arbusow; Nesterow, Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1954, p. 427,431; engl. Ausg. S. 361, 364

  摘要：

  DOI：

文献信息

• Phosphorus-containing hepatitis C serine protease inhibitors
  申请人：Moore Joel D.

  公开号：US20080039375A1

  公开（公告）日：2008-02-14

  The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I或式II的磷衍生化合物，或其药用可接受的盐、酯或前药，这些化合物抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还用作抗病毒剂。本发明进一步涉及包含上述化合物的药物组合物，用于给患有HCV感染的主体进行管理。本发明还涉及通过管理包含本发明化合物的药物组合物来治疗主体中的HCV感染的方法。
• An efficient method for the esterification of phosphonic and phosphoric acids using silica chloride
  作者：Manisha Sathe、Arvind K. Gupta、M.P. Kaushik

  DOI：10.1016/j.tetlet.2006.02.159

  日期：2006.5

  Silica chloride is used as an effective heterogeneous catalyst for the rapid esterification of alkyl/aryl phosphonic/phosphoric acids to their corresponding alkyl/aryl phosphonates/phosphates under mild conditions with quantitative yields.

  氯化硅被用作有效的非均相催化剂，用于在温和条件下以定量收率将烷基/芳基膦酸/磷酸快速酯化为其相应的烷基/芳基膦酸酯/磷酸盐。
• <i>p</i>-Toluenesulfonic Acid–Celite as a Reagent for Synthesis of Esters of Alkylphosphonic Acids under Solvent-Free Conditions
  作者：Arvind K. Gupta、Rajesh Kumar、Devendra K. Dubey、M.P. Kaushik

  DOI：10.3184/030823407x218066

  日期：2007.6

  The coupling reaction of alkylphosphonic acids and alcohols on the surface of p-toluenesulfonic acid–Celite under mild and solvent-free conditions gave the corresponding phosphonates in excellent yields. This method provides a useful rapid synthesis of phosphonates for use in the unambiguous identification of chemical warfare agents.

  在温和且无溶剂的条件下，烷基膦酸和醇在对甲苯磺酸-硅藻土表面的偶联反应以优异的产率得到相应的膦酸酯。该方法提供了一种有用的膦酸盐快速合成方法，可用于明确鉴定化学战剂。
• Selective Hydrogenation Catalyst and Methods of Making and Using Same
  申请人：Cheung Tin-Tack Peter

  公开号：US20100228065A1

  公开（公告）日：2010-09-09

  A composition comprising a supported hydrogenation catalyst comprising palladium and an organophosphorous compound, the supported hydrogenation catalyst being capable of selectively hydrogenating highly unsaturated hydrocarbons to unsaturated hydrocarbons. A method of making a selective hydrogenation catalyst comprising contacting a support with a palladium-containing compound to form a palladium supported composition, contacting the palladium supported composition with an organophosphorus compound to form a catalyst precursor, and reducing the catalyst precursor to form the catalyst. A method of selectively hydrogenating highly unsaturated hydrocarbons to an unsaturated hydrocarbon enriched composition comprising contacting a supported catalyst comprising palladium and an organophosphorous compound with a feed comprising highly unsaturated hydrocarbon under conditions suitable for hydrogenating at least a portion of the highly unsaturated hydrocarbon feed to form the unsaturated hydrocarbon enriched composition.

  一种包括支持的氢化催化剂的组合物，其中氢化催化剂包括钯和有机磷化合物，支持的氢化催化剂能够选择性地将高度不饱和烃氢化为不饱和烃。一种制备选择性氢化催化剂的方法，包括将支持物与含钯化合物接触以形成支持的钯组合物，将支持的钯组合物与有机磷化合物接触以形成催化剂前体，并还原催化剂前体以形成催化剂。一种将高度不饱和烃选择性氢化为富含不饱和烃的组合物的方法，包括将包括钯和有机磷化合物的支持催化剂与含高度不饱和烃的进料接触，在适宜的氢化条件下至少部分氢化高度不饱和烃进料以形成富含不饱和烃的组合物。
• Phosphonate Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239921A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is a phosphonate (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  提供了包括式子I或其药学上可接受的盐或组合物的补体因子D抑制剂的化合物、使用方法和制备方法，其中在A基团上的R12或R13是磷酸酯（R32）。本文所述的抑制剂靶向因子D，在替代性补体途径的早期和关键点抑制或调节补体级联反应，并减少因子D调节经典和凝集素补体途径的能力。本文所述的因子D抑制剂能够减少过度激活补体，这与某些自身免疫性、炎症性和神经退行性疾病，以及缺血再灌注损伤和癌症有关。